Surgical management of pancreatic cancer

The overall prognosis after resection for adenocarcinoma of the pancreas remains poor; however, considerable progress has been made in terms of preoperative patient selection and radiographic staging, refinements in the technical aspects of surgical care, and investigations into the role of multimodality care for patients with potentially curable, resected cancers. Improvements in endoscopic decompression of malignant biliary obstruction have decreased the need for palliative bypass operations and have focused current surgical issues on ways to improve clinical outcomes after potentially curative resections. Controversies such as whether or not to perform extended lymph node dissections and standard versus pylorus-preserving resections have been addressed by randomized, prospective clinical trials. Major venous resections secondary to local tumor extension are now performed without an increase in morbidity or mortality and with survival rates comparable to standard resections. The impact of surgical specialization and regionalization of referrals to tertiary care centers is evident in markedly improved perioperative mortality rates. Neoadjuvant therapy is an area of current clinical investigation. This article describes the current preoperative, intraoperative, and postoperative issues in the surgical management of pancreatic cancer.     

Multimodale Therapie beim Adenokarzinom des Ösophagus und des ösophagogastralen Übergangs

Late diagnosis and early metastatic spread have prompted research groups to include chemotherapy and radiotherapy in addition to resection into the treatment concept for many years and to investigate multimodal therapy within randomized clinical trials. Surgical resection remains the backbone of the therapeutic concept in esophageal adenocarcinoma. Furthermore, preoperative therapy has now become an international standard of care. There is some evidence that combined radiochemotherapy is superior to preoperative chemotherapy alone and appears to reduce the number of incomplete tumor resections. Moreover, preoperative radiochemotherapy increases the rate of pathologic complete remissions and subsequently local tumor control. However, it remains unclear whether preoperative radiochemotherapy may further improve the prognosis compared to preoperative chemotherapy in patients with adenocarcinoma of the esophagus. The role of targeted therapies is unknown at present.     

Treatment of Barrett’s esophagus with high-grade dysplasia

The incidence of esophageal adenocarcinoma is increasing in the USA, now accounting for at least 4% of US cancer-related deaths. Barrett’s esophagus is the main risk factor for the development of esophageal adenocarcinoma. The annual incidence of development of adenocarcinoma in Barrett’s esophagus is approximately 0.5% per year, representing at least a 30–40-fold increase in risk from the general population. High-grade dysplasia is known to be the most important risk factor for progression to adenocarcinoma. Traditionally, esophagectomy has been the standard treatment for Barrett’s esophagus with high-grade dysplasia. This practice is supported by studies revealing unexpected adenocarcinoma in 29–50% of esophageal resection specimens for high-grade dysplasia. In addition, esophagectomy employed prior to tumor invasion of the muscularis mucosa results in 5-year survival rates in excess of 80%. Although esophagectomy can result in improved survival rates for early-stage cancer, it is accompanied by significant morbidity and mortality. Recently, more accurate methods of surveillance and advances in endoscopic therapies have allowed scientists and clinicians to develop treatment strategies with lower morbidity for high-grade dysplasia. Early data suggests that carefully selected patients with high-grade dysplasia can be managed safely with endoscopic therapy, with outcomes comparable to surgery, but with less morbidity. This is an especially attractive approach for patients that either cannot tolerate or decline surgical esophagectomy. For patients that are surgical candidates, high-volume centers have demonstrated improved morbidity and mortality rates for esophagectomy. The addition of laparoscopic esophagectomy adds a less invasive surgical resection to the treatment armanentarium. Esophagectomy will remain the gold-standard treatment of Barrett’s esophagus with high-grade dysplasia until clinical research validates the role of endoscopic therapies. Current treatment strategies for Barrett’s esophagus with high-grade dysplasia will be reviewed.     

Lessons learned from the European thoracic surgery database: The composite performance score

BackgroundThis study reports the methods used to review the Composite Performance Score (CPS) along with a reference table, which will be used in the upcoming ESTS Quality Certification Program.MethodsData from 4303 patients who underwent pulmonary resection (July 2007–January 2010) were captured in the ESTS database and used for the present analysis. Only patients submitted from units contributing at least 100 consecutive lung resections were used for developing the score.According to the best available evidence the following measures were selected for each surgical domain: preoperative care (1. % of DLCO measurement in patients submitted to major anatomic resections; 2. % of preoperative invasive mediastinal staging in patients with clinically suspicious N2 disease), operative care (% of systematic lymph node dissection), outcomes (risk-adjusted cardiopulmonary morbidity and mortality rates). Morbidity and mortality risk-models were developed by logistic regression and validated by bootstrap analyses. Individual processes and outcomes scores were rescaled according to their standard deviations and summed to generate the CPS. Units were rated accordingly and a percentile reference table was produced.ResultsRisk-adjusted survival and absence of morbidity rates varied from 91.5% to 100%, and from 50.2% to 97.5%, respectively. CPS ranged from ?4.038 to 1.24. The 50% percentile of CPS corresponded to 0.404.ConclusionsA revised Composite Performance Score was developed and a reference table presented to be used as a benchmark for the ESTS Quality Certification program.     

Mortality following liver resection in US medicare patients: Does the presence of a liver transplant program affect outcome?

BACKGROUND: Hepatic resection is a complicated procedure, at times associated with significant morbidity. Liver transplantation programs may improve outcomes following resective liver surgery at the institutional level by a number of means, including: availability of ancillary services and personnel, specialized critical care, and added surgical expertise. OBJECTIVES: To determine if the presence of a liver transplant program at a center improves outcomes following hepatic resection when compared to centers without an associated liver transplant program. METHODS: Using data from the national Medicare claims database, 30-day mortality following all hepatic resections performed over a 2-year period (1999, 2000) were studied. Regression techniques were used to assess the relationship between mortality at centers with an associated liver transplant program in comparison to those without, while controlling for potential confounding factors. RESULTS: The proportion of patients dying within 30 days among 4,661 patients that underwent hepatic resection was 6.65%. Factors that did increase the risk of dying after hepatic resection included: urgent or emergent surgery (vs. elective), primary liver cancer (vs. metastatic), male sex, increasing comorbidity score, low hospital volume, and extent of surgery. The presence of a liver transplant program within a center was not associated with any improvement in mortality. CONCLUSION: At an institutional level, the presence of a liver transplant program was not associated with decreased 30-day mortality following hepatic resection.     

Advances in the surgical management of pancreatic cancer

Pancreatic cancer continues to pose a major public health concern and clinical challenge. The incidence of the disease is nearly equivalent to the death rate associated with the diagnosis of pancreatic cancer. Thus, there exists a need for continued improvement in the diagnostic, therapeutic and palliative care of these patients. Surgeons play an integral role in the management of pancreatic cancer patients, with surgery providing the only potentially curative intervention for the disease. Specialized centers have reported improved hospital morbidity, mortality and survival after pancreaticoduodenectomy; however, disease-specific survival after surgical resection remains dismal. An emphasis therefore has been placed upon the accurate preoperative staging of patients in order to identify those patients who would benefit from a complete surgical resection. Surgical staging that incorporates the use of laparoscopic techniques now complements non-surgical methods of staging, including helical CT scans. While there is no defined preoperative staging approach, it is imperative that centers identify areas of expertise and experience with available modalities in any combination to effect accurate staging. Once patients have been accurately staged and deemed resectable, there exist various methods for resection of pancreas lesions, which include the standard "Whipple procedure," pylorus-preserving pancreaticoduodenectomy, regional pancreatectomy, total pancreatectomy, and en bloc vascular resection, where appropriate. Reconstructive techniques have been explored and include methods of pancreaticojejunostomy and pancreaticogastrostomy with or without pancreatic ductal stents and intraoperatively placed closed suction drains. Perioperative mortality following pancreaticoduodenectomy for cancer has a general reported incidence of 1% to 4% at high volume centers experienced with the operation. Morbidity however still remains high with that of delayed gastric emptying, pancreatic anastomotic leak or fistula, intraabdominal abscess, and hemorrhage as the leading reported complications. Researchers have investigated several agents and strategies to decrease or prevent the potential morbidity of these complications including the use of octreotide, drainage of the pancreatic bed and institution of early enteral feeding. Unfortunately, the majority of patients with pancreatic cancer present with either locally advanced or metastatic disease that precludes operative cure. The expected survival for these patients is usually less than six months from diagnosis. Therefore, a goal of therapy should be adequate palliation of symptoms of pain, biliary or duodenal obstruction and improvement of remaining quality of life with the least degree of morbidity possible.     

Surgery insight: surgical management of pancreatic cancer

Pancreatic ductal adenocarcinoma is a common malignancy of the gastrointestinal tract. The number of new cases diagnosed and the number of deaths each year are almost identical, demonstrating the particularly dismal prognosis for patients affected by this disease. Despite recent advances in the field of medical and radiation oncology, and the introduction of neoadjuvant and adjuvant regimens, surgery remains the single most important modality for the treatment of pancreatic ductal adenocarcinoma. Surgery for pancreatic cancer is widely viewed as a complex procedure associated with considerable perioperative morbidity and mortality. Many aspects of surgery for pancreatic cancer, such as the extent of resection, the value of vascular resection, the use of laparoscopy, and the importance of treatment at high-volume centers, are currently under debate. This Review describes the current status of surgical treatment for pancreatic ductal adenocarcinoma, and highlights the new developments in this field.     

Improving outcomes after esophagectomy: the impact of operative volume

Once considered an uncommon malignancy, primary esophageal adenocarcinoma has increased steadily in incidence over the past three decades. Despite advances in multimodality therapy, the prognosis for this tumor is generally poor. Surgical resection and reconstruction of the upper gastrointestinal tract is the current standard of care for localized esophageal cancer, but despite advances in perioperative care, still remains a relatively high-risk surgical procedure. Increasing numbers of reports published over the past decade have documented a clear volume-outcome relationship for several complex surgical procedures, and in particular for esophagectomy. The clinical implications of this association are reviewed in this section.     

Postoperative care after esophagectomy: the surgeon's view

Although in the past esophagectomy was associated with high rates of morbidity and mortality, currently specialized centers have reported reduced hospital death rates of less than 10%. This reduction has been mainly attributed to preoperative patient selection, improvements in anesthesia, surgical techniques, and postoperative care management. In recent years, clinical care pathways, namely physician-directed clinical plans, have been developed to standardize postoperative care after specific surgical procedures: primary goals are improvement in quality of care and reduction in hospital costs. These pathways could be planned after identification of the complications with the highest incidence and the highest hospital costs in order to optimally allocate resources. Aim of this study is to delineate an ideal clinical care pathway after esophagectomy by reporting the most common complications with an overview of advances in perioperative care and providing pointers to what might be achievable.     

Treatment results of curative gastric resection from a specialist Australian unit: low volume with satisfactory outcomes

Background

The incidence of gastric cancer is decreasing in Australia, yet it remains a common cause of cancer-related mortality. Surgical resection remains the cornerstone of curative treatment. High-volume specialized units have reported superior perioperative and oncological outcomes. The role of D2 lymphadenectomy has been controversial as a result of concerns over increased morbidity. Our aim is to report the perioperative and oncological outcomes of curative gastric resection from a specialist Australian upper GI unit.

Methods

Data from a prospectively maintained database were reviewed for all patients undergoing curative resection for gastric adenocarcinoma from a single unit during a 12-year period. Perioperative and long-term outcomes were compiled.

Results

There were 255 curative gastric resections during 12 years. An R0 resection was performed in 96 % with a perioperative mortality rate of 1.6 %. A D2 dissection was performed in 85 % of cases in the past 6 years, with no increase in perioperative morbidity or mortality detected. The 5-year overall survival was 53 %.

Conclusion

Our results demonstrate that both short- and long-term outcomes of surgical resection in gastric cancer patients, comparable to international high-volume centers, can be achieved in an Australian upper GI unit. A D2 lymph node dissection can be performed safely without any increase in perioperative risk in a specialist unit that has the necessary training but also the perioperative support structures to manage these complex patients.     

Impact of surgical volume of centers on post-operative outcomes from cytoreductive surgery and hyperthermic intra-peritoneal chemoperfusion

Complex surgical operations performed at centers of high volume have improved outcomes due to improved surgical proficiency, and betters systems of care including avoidance of errors. Cytoreductive surgery (CRS) and hyperthermic intra-peritoneal chemoperfusion (HIPEC), which has been shown to be an oncologically effective strategy for peritoneal carcinomatosis (PC), is one such procedure with significant morbidity and mortality. The learning curve to reach technical proficiency in CRS + HIPEC is about 140-220 cases for a center. Focus on improving surgical proficiency through training, improving systems of care through partnerships and reporting mechanisms for quality could reduce the time to proficiency.     

Development and evolution of pelvic exenteration: historical notes.

Fifty years after the development of pelvic exenteration, the operation remains a gold standard in the surgical management of advanced pelvic malignancy. The operation has evolved through several predictable phases including technical improvements, lowered morbidity and mortality, and improved patient selection. Despite progress in supportive peri-operative care, pelvic exenteration is a major undertaking that should be performed in centers with proven interest and expertise in the field. We trace the early developments of the operation, the period of maturation, and the current place of this procedure in the armamentarium of the oncologic surgeon.     

Laparoscopic liver resection: Current role and limitations

Laparoscopic liver resection (LLR) for the treatment of benign and malignant liver lesions is often performed at specialized centers. Technological advances, such as laparoscopic ultrasonography and electrosurgical tools, have afforded surgeons simultaneous improvements in surgical technique. The utilization of minimally invasive techniques for liver resection has been reported to reduce operative time, decrease blood loss, and shorten length of hospital stay with equivalent postoperative mortality and morbidity rates compared to open liver resection (OLR). Non-anatomic liver resection and left lateral sectionectomy are now routinely performed laparoscopically at many institutions. Furthermore, major hepatic resections are performed by pure laparoscopy, hand-assisted technique, and the hybrid method. In addition, robotic surgery and single port surgery are revealing early promising results. The consensus recommendation for the treatment of benign liver disease and malignant lesions remains unchanged when considering a laparoscopic approach, except when comorbidities and anatomic limitations of the liver lesion preclude this technique. Disease free and survival rates after LLR for hepatocellular carcinoma and metastatic colon cancer correspond to OLR. Patient selection is a significant factor for these favorable outcomes. The limitations include LLR of superior and posterior liver lesions; however, adjustments in technique may now consider a laparoscopic approach as a viable option. As growing data continue to reveal the feasibility and efficacy of laparoscopic liver surgery, this skill is increasingly being adopted by hepatobiliary surgeons. Although the full scope of laparoscopic liver surgery remains infrequently used by many general surgeons, this technique will become a standard in the treatment of liver diseases as studies continue to show favorable outcomes.     

Technique and role of minimally invasive esophagectomy for premalignant and malignant diseases of the esophagus

Esophagectomy remains the standard of care in most centers for patients with resectable esophageal cancer. The choice of incision and conduit has remained the subject of much discussion. Open surgical approaches include the Ivor Lewis, transhiatal, left thoracoabdominal, three-hole, and left thoracoabdominal with left neck anastomosis. These techniques will be covered in the article by. Regardless of the approach, esophagectomy has been associated with considerable morbidity and mortality. Although modern anesthetic and surgical care has reduced the risks of esophagectomy, the incidence of major or minor complications is still approximately 70% to 80%, and the hospital mortality rate is 4% to 7% at experienced centers. In the hopes of reducing perioperative morbidity, minimally invasive techniques have been increasingly applied to esophageal surgery. Experience with laparoscopic antireflux surgery has allowed us to perform more and more complex surgery on the stomach and esophagus and, in 1995, surgeons began to report their experiences with minimally invasive esophagectomy using various techniques.     

Transthoracic En-bloc Esophagectomy

In patients with esophageal carcinoma surgical resection remains the standard of curativetreatment.For locally advanced tumors (pT1sm-pT3) transthoracic esophagectomy with extended lym-phadenectomy is the standard surgical procedure since it offers a complete removal of the primary tumorand possible lymph node metastases.This surgical resection is appropriate for squamous cell but alsoadenocarcinoma of the esophagus because both histological entities demonstrate a lymphatic spread tothe abdominal compartment and the upper mediastinum.In-hospital mortality rates are between 6% and9%;anastomotic leakage and pulmonary complications mainly contribute to postoperative morbidity.Interms of 5-year survival the transthoracic procedure offers a better prognosis compared to the transhiatalresection.     

经胸食管全切除术

In patients with esophageal carcinoma surgical resection remains the standard of curative treatment. For locally advanced tumors (pTlsm-pT3) transthoracic esophagectomy with extended lymphadenectomy is the standard surgical procedure since it offers a complete removal of the primary tumor and possible lymph node metastases. This surgical resection is appropriate for squamous cell but also adenocarcinoma of the esophagus because both histological entities demonstrate a lymphatic spread to the abdominal compartment and the upper mediastinum. In-hospital mortality rates are between 6% and 9%; anastomotic leakage and pulmonary complications mainly contribute to postoperative morbidity. In terms of 5-year survival the transthoracic procedure offers a better prognosis compared to the transhiatal resection.     

Temporal trends in survival after surgical resection of localized non-small cell lung cancer

To test whether modern preoperative staging modalities and perioperative care improve survival after resection of localized non-small cell lung cancer (NSCLC), we retrospectively reviewed outcomes of 454 patients with NSCLC resected from 1947 through 1969 (designated pre-1970 cases), and 540 patients with cancers resected from 1981 through 1994 (designated post-1980 cases). Mean ages, histological subtypes, surgical stages, and types of surgical procedures differed significantly between the two groups. Compared with pre-1970 cases, post-1980 cases were older, had more adenocarcinoma and less squamous cell carcinoma, and had lesser proportions of advanced stage disease. Postoperative (day 30) mortality was significantly higher for resections of localized (stages 1 and 2) NSCLC prior to 1970. For patients surviving at least 30 days after surgery, subsequent survival after resection of localized NSCLC differed minimally between pre-1970 and post-1980 groups. We conclude that perioperative mortality after resection of localized NSCLC improved, but subsequent postoperative survival for these patients did not significantly improve over the 45-year period studied.     

Elective surgery for gastrointestinal tumours in the aged

The geriatric population is expanding and clinical decision-making is oftencomplicated by the effects of aging. Age should not be the only parameterconsidered when addressing medical problems. Elderly subjects have been deniedsurgery because of their presumed higher mortality and morbidity. The presentreview summarises the physiology of the aged and discusses operative risks,mortality and morbidity rates as well as therapeutic results for the differentgastrointestinal sites when affected by cancer. Reports on surgical treatmentsare revisited and compared to the same procedures delivered to youngerpatients in the context of the ethical issue of offering the best care toevery patient. Elective operations by surgical oncologists are found to besafe with the exception of major liver resections. Complication rates and meanhospital stay do not differ between the two age groups provided the procedureis conducted with the best-known technique in expert hands. A drop inoperative morbidity has occurred in the past three decades. Severalinvestigators have emphasised the marked increase in morbidity and mortalityexperienced by elderly patients when undergoing emergency procedures.Associated diseases have to be properly assessed, as the aged have a frailphysiologic balance with a reduced capacity for recovery from traumatic eventsincluding major surgical procedures. Careful preoperative evaluation,intraoperative conduct and postoperative care are presently achieved in almostevery major hospital. Good clinical practice is based on the balance betweenprobability of cure and toxic effects. Treatment of the elderly should nolonger be based on untested beliefs and personal opinions. The aged should beaccrued for prospective clinical evaluation and meanwhile should not be deniedoptimal surgical treatment.     

Hospital volume and hospital mortality for esophagectomy

BACKGROUND: Hospital mortality after esophagectomy has decreased from 29% to 7.5% over the last decades because of improved surgical techniques and better perioperative care. Suggestions have been made that a further decrease in hospital mortality may be achieved by centralization of esophagectomies in high volume centers. METHODS: The effect of hospital volume on hospital mortality after esophagectomy in the Netherlands was analyzed based on data from the Dutch National Medical Registry and the Dutch Network and National Database for Pathology over the period 1993-1998. RESULTS: Annually, approximately 310 (range, 264-321) esophagectomies are performed in the Netherlands. Fifty-two percent are performed in 43-55 low volume centers (1-10 resections a year). Six percent are performed in 1-3 medium volume centers (11-20 resections a year). The remainder (42%) is performed in two high volume centers (> 50 resections a year). Hospital mortality is 12.1%, 7.5% and 4.9% respectively (P < 0.001). The high volume centers seem to see slightly more advanced tumors than the low and medium volume centers. CONCLUSIONS: There is a significant (inverse) relation between hospital mortality and hospital volume for esophageal resection in the Netherlands. Although hospital mortality is not the only measure for quality of care, these data suggest a potential beneficial effect to centralization of esophagectomy in the Netherlands.     

Laparoscopic distal pancreatectomy for adenocarcinoma: safe and reasonable?

As a result of technological advances during the past two decades, surgeons now use minimally invasive surgery (MIS) approaches to pancreatic resection more frequently, yet the role of these approaches for pancreatic ductal adenocarcinoma resections remains uncertain, given the aggressive nature of this malignancy. Although there are no controlled trials comparing MIS technique to open surgical technique, laparoscopic distal pancreatectomy for pancreatic adenocarcinoma is performed with increasing frequency. Data from retrospective studies suggest that perioperative complication profiles between open and laparoscopic distal pancreatectomy are similar, with perhaps lower blood loss and fewer wound infections in the MIS group. Concerning oncologic outcomes, there appear to be no differences in the rate of achieving negative margins or in the number of lymph nodes (LNs) resected when compared to open surgery. There are limited recurrence and survival data on laparoscopic compared to open distal pancreatectomy for pancreatic adenocarcinoma, but in the few studies that assess long term outcomes, recurrence rates and survival outcomes appear similar. Recent studies show that though laparoscopic distal pancreatectomy entails a greater operative cost, the associated shorter length of hospital stay leads to decreased overall cost compared to open procedures. Multiple new technologies are emerging to improve resection of pancreatic cancer. Robotic pancreatectomy is feasible, but there are limited data on robotic resection of pancreatic adenocarcinoma, and outcomes appear similar to laparoscopic approaches. Additionally fluorescence-guided surgery represents a new technology on the horizon that could improve oncologic outcomes after resection of pancreatic adenocarcinoma, though published data thus far are limited to animal models. Overall, MIS distal pancreatectomy appears to be a safe and reasonable approach to treating selected patients with pancreatic ductal adenocarcinoma, though additional studies of long-term oncologic outcomes are merited. We review existing data on MIS distal pancreatectomy for pancreatic ductal adenocarcinoma.